Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications

References

• Quigley EM. Leaky gut - concept or clinical entity? Curr Opin Gastroenterol. 2016;32(2):74–79.
   PubMed Web of Science ®Google Scholar
• Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12(5):319–330.
   PubMedGoogle Scholar
• Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta. 2006;1765(2):189–222.
   PubMed Web of Science ®Google Scholar
• Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008;105(39):15064–15069.
   PubMed Web of Science ®Google Scholar
• Xie YR, Liu SL, Liu X, et al. Intestinal microbiota and innate immunity-related gene alteration in cirrhotic rats with liver transplantation. Transplant Proc. 2011;43(10):3973–3979.
   PubMed Web of Science ®Google Scholar
• Grewal RKMA. Ethanol induced changes in glycosylation of mucins in rat intestine. Ann Gastroenterol. 2009;22(3):178–183.
   Google Scholar
• Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013;58(1):108–119.
   PubMed Web of Science ®Google Scholar
• Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14(3):141–153.
   PubMed Web of Science ®Google Scholar
• Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809.
   PubMed Web of Science ®Google Scholar
• Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004;286(6):C1213–C1228.
   PubMed Web of Science ®Google Scholar
• Du Plessis J, Vanheel H, Janssen CE, et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol. 2013;58(6):1125–1132.
   PubMed Web of Science ®Google Scholar
• Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42(4):439–446.
   PubMed Web of Science ®Google Scholar
• Fouts DE, Torralba M, Nelson KE, et al. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012;56(6):1283–1292.
   PubMed Web of Science ®Google Scholar
• Pijls KE, Jonkers DM, Elamin EE, et al. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int. 2013;33(10):1457–1469.
   PubMed Web of Science ®Google Scholar
• Karthikeyan A, Mohan P, Chinnakali P, et al. Elevated systemic zonula occludens 1 is positively correlated with inflammation in cirrhosis. Clin Chim Acta. 2018;480:193–198.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Basili S, Carnevale R, et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology. 2017;65(2):571–581.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology. 2018 Apr 17.
   PubMedGoogle Scholar
• Ram AK, Pottakat B, Vairappan B. Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma. BMC Cancer. 2018;18(1):572.
   PubMedGoogle Scholar
• Ye D, Guo S, Al-Sadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;141(4):1323–1333.
   PubMed Web of Science ®Google Scholar
• Munoz L, Albillos A, Nieto M, et al. Mesenteric Th1 polarization and monocyte TNF-alpha production: first steps to systemic inflammation in rats with cirrhosis. Hepatology. 2005;42(2):411–419.
   PubMed Web of Science ®Google Scholar
• Genesca J, Marti R, Rojo F, et al. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut. 2003;52(7):1054–1059.
   PubMed Web of Science ®Google Scholar
• Du Plessis J, van der Merwe SW. Reply to: “Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis: the pivotal role of enterocyte tight junctions and future perspectives”. J Hepatol. 2013;59(5):1146–1147.
   PubMed Web of Science ®Google Scholar
• Such J, Guardiola JV, De Juan J, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002;14(4):371–376.
   PubMed Web of Science ®Google Scholar
• Wen JB, Zhu FQ, Chen WG, et al. Oxymatrine improves intestinal epithelial barrier function involving NF-kappaB-mediated signaling pathway in CCl4-induced cirrhotic rats. PLoS One. 2014;9(8):e106082.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology. 2002;35(3):622–629.
   PubMed Web of Science ®Google Scholar
• Chiva M, Guarner C, Peralta C, et al. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol. 2003;15(2):145–150.
   PubMed Web of Science ®Google Scholar
• Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. Toxicology. 2002;181-182:219–222.
   PubMed Web of Science ®Google Scholar
• Corradi F, Brusasco C, Fernandez J, et al. Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. Dig Liver Dis. 2012;44(3):239–244.
   PubMedGoogle Scholar
• Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350(6262):830–834.
   PubMed Web of Science ®Google Scholar
• Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013;33(1):31–39.
   PubMed Web of Science ®Google Scholar
• Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313–323.
   PubMed Web of Science ®Google Scholar
• Hase K, Kawano K, Nochi T, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature. 2009;462(7270):226–230.
   PubMed Web of Science ®Google Scholar
• Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2(4):361–367.
   PubMed Web of Science ®Google Scholar
• Knoop KA, Newberry RD. Isolated lymphoid follicles are dynamic reservoirs for the induction of intestinal IgA. Front Immunol. 2012;3:84.
   PubMed Web of Science ®Google Scholar
• Vaishnava S, Behrendt CL, Ismail AS, et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A. 2008;105(52):20858–20863.
   PubMed Web of Science ®Google Scholar
• Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol. 2000;1(2):113–118.
   PubMed Web of Science ®Google Scholar
• Ogle CK, Noel JG, Guo X, et al. The ability of endotoxin-stimulated enterocytes to produce bactericidal factors. Crit Care Med. 2002;30(2):428–434.
   PubMed Web of Science ®Google Scholar
• Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14(10):996–1006.
   PubMed Web of Science ®Google Scholar
• Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147-163.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–1396.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Gerardi V, Gasbarrini A. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Rev Gastroenterol Hepatol. 2016;10(2):215–227.
   PubMed Web of Science ®Google Scholar
• Theocharidou E, Dhar A, Patch D. Gastrointestinal Motility Disorders and Their Clinical Implications in Cirrhosis. Gastroenterol Res Pract. 2017;2017:8270310.
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Thuluvath PJ. Autonomic neuropathy may be associated with delayed orocaecal transit time in patients with cirrhosis. Auton Neurosci. 2005;118(1–2):135–139.
   PubMed Web of Science ®Google Scholar
• Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. Lancet. 1992;339(8807):1462–1464.
   PubMed Web of Science ®Google Scholar
• Giannelli V, Di Gregorio V, Iebba V, et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol. 2014;20(45):16795–16810.
   PubMed Web of Science ®Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–174.
   PubMed Web of Science ®Google Scholar
• Ding JW, Andersson R, Soltesz V, et al. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur Surg Res. 1993;25(1):11–19.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–3925.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Zuniga V, Bartoli R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37(3):551–557.
   PubMed Web of Science ®Google Scholar
• Bertok L. Bile acids in physico-chemical host defence. Pathophysiology. 2004;11(3):139–145.
   PubMedGoogle Scholar
• Ridlon JM, Alves JM, Hylemon PB, et al. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013;4(5):382–387.
   PubMed Web of Science ®Google Scholar
• Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–955.
   PubMed Web of Science ®Google Scholar
• Worlicek M, Knebel K, Linde HJ, et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut. 2010;59(8):1127–1134.
   PubMed Web of Science ®Google Scholar
• Keita AV, Soderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil. 2010;22(7):718–733.
   PubMed Web of Science ®Google Scholar
• Hodin CM, Lenaerts K, Grootjans J, et al. Starvation compromises Paneth cells. Am J Pathol. 2011;179(6):2885–2893.
   PubMed Web of Science ®Google Scholar
• Nazli A, Yang PC, Jury J, et al. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am J Pathol. 2004;164(3):947–957.
   PubMed Web of Science ®Google Scholar
• Casafont F, Sanchez E, Martin L, et al. Influence of malnutrition on the prevalence of bacterial translocation and spontaneous bacterial peritonitis in experimental cirrhosis in rats. Hepatology. 1997;25(6):1334–1337.
   PubMed Web of Science ®Google Scholar
• Norman K, Pirlich M, Schulzke JD, et al. Increased intestinal permeability in malnourished patients with liver cirrhosis. Eur J Clin Nutr. 2012;66(10):1116–1119.
   PubMed Web of Science ®Google Scholar
• Sheflin AM, Melby CL, Carbonero F, et al. Linking dietary patterns with gut microbial composition and function. Gut Microbes. 2017;8:113-129.
   Web of Science ®Google Scholar
• Sharon G, Sampson TR, Geschwind DH, et al. The central nervous system and the gut microbiome. Cell. 2016;167(4):915–932.
   PubMed Web of Science ®Google Scholar
• Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079–1089.
   PubMed Web of Science ®Google Scholar
• Kamada N, Chen GY, Inohara N, et al. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14(7):685–690.
   PubMed Web of Science ®Google Scholar
• Caricilli AM, Castoldi A, Camara NO. Intestinal barrier: A gentlemen’s agreement between microbiota and immunity. World J Gastrointest Pathophysiol. 2014;5(1):18–32.
   PubMedGoogle Scholar
• Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002;99(24):15451–15455.
   PubMed Web of Science ®Google Scholar
• Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
   PubMed Web of Science ®Google Scholar
• Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Gerardi V, Pecere S, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015;21(43):12322–12333.
   PubMed Web of Science ®Google Scholar
• Lu H, Wu Z, Xu W, et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011;61(3):693–703.
   PubMed Web of Science ®Google Scholar
• Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol. 2013;13:175.
   Web of Science ®Google Scholar
• Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562–572.
   PubMed Web of Science ®Google Scholar
• Tuomisto S, Pessi T, Collin P, et al. Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol. 2014;14:40.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhai H, Geng J, et al. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013;108(10):1601–1611.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62(4):1260–1271.
   PubMed Web of Science ®Google Scholar
• Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–947.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–2967.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97(9):2364–2370.
   PubMed Web of Science ®Google Scholar
• Casafont Morencos F, De Las Heras Castano G, Martin RL, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1996;41(3):552–556.
   PubMed Web of Science ®Google Scholar
• Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28(5):1187–1190.
   PubMed Web of Science ®Google Scholar
• Yang CY, Chang CS, Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol. 1998;33(8):867–871.
   PubMed Web of Science ®Google Scholar
• Chang CS, Yang SS, Kao CH, et al. Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol. 2001;36(1):92–96.
   PubMed Web of Science ®Google Scholar
• Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29(12):1273–1281.
   PubMed Web of Science ®Google Scholar
• Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010;55(5):1465–1471.
   PubMed Web of Science ®Google Scholar
• Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology. 1993;17(5):828–832.
   PubMed Web of Science ®Google Scholar
• Thalheimer U, De Iorio F, Capra F, et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol. 2010;22(10):1228–1234.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Casafont F, Guerra A, et al. Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis. Rev Esp Enferm Dig. 2005;97(11):805–814.
   PubMedGoogle Scholar
• Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31(1):43–48.
   PubMed Web of Science ®Google Scholar
• Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol. 1997;26(6):1372–1378.
   PubMed Web of Science ®Google Scholar
• Steffen EK, Berg RD. Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. Infect Immun. 1983;39(3):1252–1259.
   PubMed Web of Science ®Google Scholar
• Lichtman SN, Sartor RB, Keku J, et al. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology. 1990;98(2):414–423.
   PubMed Web of Science ®Google Scholar
• Stewart JJ, Battarbee HD, Farrar GE, et al. Intestinal myoelectrical activity and transit time in chronic portal hypertension. Am J Physiol. 1992;263(4 Pt 1):G474–G479.
   PubMedGoogle Scholar
• Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209.
   PubMed Web of Science ®Google Scholar
• Berg RD. Bacterial translocation from the gastrointestinal tract. J Med. 1992;23(3–4):217–244.
   PubMedGoogle Scholar
• Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422–433.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675–680.
   PubMed Web of Science ®Google Scholar
• Hapfelmeier S, Lawson MA, Slack E, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010;328(5986):1705–1709.
   PubMed Web of Science ®Google Scholar
• Gautreaux MD, Deitch EA, Berg RD. T lymphocytes in host defense against bacterial translocation from the gastrointestinal tract. Infect Immun. 1994;62(7):2874–2884.
   PubMed Web of Science ®Google Scholar
• Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 1995;22(2):165–172.
   PubMed Web of Science ®Google Scholar
• Bellot P, Garcia-Pagan JC, Frances R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):2044–2052.
   PubMed Web of Science ®Google Scholar
• Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34(1):32–37.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Lee FY, Barden GE, et al. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology. 1995;108(6):1835–1841.
   PubMed Web of Science ®Google Scholar
• Munoz L, Jose Borrero M, Ubeda M, et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology. 2012;56(5):1861–1869.
   PubMed Web of Science ®Google Scholar
• Ubeda M, Munoz L, Borrero MJ, et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology. 2010;52(6):2086–2095.
   PubMed Web of Science ®Google Scholar
• Teltschik Z, Wiest R, Beisner J, et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology. 2012;55(4):1154–1163.
   PubMed Web of Science ®Google Scholar
• Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53(1):96–105.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil AC, Snoek AM, van ‘t Veer C, et al. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest. 2001;107(2):225–234.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil AC, Rousseau CH, Hartung T, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003;170(3):1399–1405.
   PubMed Web of Science ®Google Scholar
• Berbee JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res. 2005;11(2):97–103.
   PubMedGoogle Scholar
• Roth RI, Levin FC, Levin J. Distribution of bacterial endotoxin in human and rabbit blood and effects of stroma-free hemoglobin. Infect Immun. 1993;61(8):3209–3215.
   PubMed Web of Science ®Google Scholar
• Fukui H, Tsujita S, Matsumoto M, et al. Endotoxin inactivating action of plasma in patients with liver cirrhosis. Liver. 1995;15(2):104–109.
   PubMedGoogle Scholar
• Schafer C, Parlesak A, Schutt C, et al. Concentrations of lipopolysaccharide-binding protein, bactericidal/permeability-increasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease. Alcohol Alcohol. 2002;37(1):81–86.
   PubMed Web of Science ®Google Scholar
• Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012;590(3):447–458.
   PubMed Web of Science ®Google Scholar
• Ladman AJ, Padykula HA, Strauss EW. A morphological study of fat transport in the normal human jejunum. Am J Anat. 1963;112(389–419).
   PubMedGoogle Scholar
• Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176(6):1665–1671.
   PubMed Web of Science ®Google Scholar
• Pugin J, Schurer-Maly CC, Leturcq D, et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A. 1993;90(7):2744–2748.
   PubMed Web of Science ®Google Scholar
• Schumann RR, Kirschning CJ, Unbehaun A, et al. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol Cell Biol. 1996;16(7):3490–3503.
   PubMed Web of Science ®Google Scholar
• Landmann R, Knopf HP, Link S, et al. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun. 1996;64(5):1762–1769.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21(4):317–337.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–745.
   PubMed Web of Science ®Google Scholar
• Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139(1):323–334 e327.
   PubMed Web of Science ®Google Scholar
• Hackstein CP, Assmus LM, Welz M, et al. Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. Gut. 2017;66(3):507–518.
   PubMed Web of Science ®Google Scholar
• Frances R, Gonzalez-Navajas JM, Zapater P, et al. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin Exp Immunol. 2007;150(2):230–237.
   PubMed Web of Science ®Google Scholar
• Pinero P, Juanola O, Caparros E, et al. Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis. Sci Rep. 2017;7:46425.
   PubMed Web of Science ®Google Scholar
• Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–265.
   PubMed Web of Science ®Google Scholar
• Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826–837.
   PubMed Web of Science ®Google Scholar
• Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103(1):264–274.
   PubMed Web of Science ®Google Scholar
• Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158–1172.
   PubMed Web of Science ®Google Scholar
• Taylor CT, Dzus AL, Colgan SP. Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha. Gastroenterology. 1998;114(4):657–668.
   PubMed Web of Science ®Google Scholar
• Frances R, Chiva M, Sanchez E, et al. Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites. J Hepatol. 2007;46(5):797–803.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yoshinaga N, Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem. 2011;286(36):31263–31271.
   PubMed Web of Science ®Google Scholar
• Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis. 1999;19(4):411–426.
   PubMed Web of Science ®Google Scholar
• Tepperman BL, Brown JF, Whittle BJ. Nitric oxide synthase induction and intestinal epithelial cell viability in rats. Am J Physiol. 1993;265(2 Pt 1):G214–G218.
   PubMedGoogle Scholar
• McAvoy NC, Semple S, Richards JM, et al. Differential visceral blood flow in the hyperdynamic circulation of patients with liver cirrhosis. Aliment Pharmacol Ther. 2016;43(9):947–954.
   PubMed Web of Science ®Google Scholar
• Brinch K, Moller S, Bendtsen F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol. 2003;39(1):24–31.
   PubMed Web of Science ®Google Scholar
• Frances R, Munoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004;53(6):860–864.
   PubMed Web of Science ®Google Scholar
• Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18(5):1139–1143.
   PubMed Web of Science ®Google Scholar
• Albillos A, De La Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37(1):208–217.
   PubMed Web of Science ®Google Scholar
• Steib CJ, Hartmann AC, V Hesler C, et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest. 2010;90(7):1024–1032.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zou L, Jagavelu K, et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012;56(4):893–899.
   PubMed Web of Science ®Google Scholar
• Bhimani EK, Serracino-Inglott F, Sarela AI, et al. Hepatic and mesenteric nitric oxide synthase expression in a rat model of CCl(4)-induced cirrhosis. J Surg Res. 2003;113(1):172–178.
   PubMed Web of Science ®Google Scholar
• Mishima S, Xu D, Lu Q, et al. Bacterial translocation is inhibited in inducible nitric oxide synthase knockout mice after endotoxin challenge but not in a model of bacterial overgrowth. Arch Surg. 1997;132(11):1190–1195.
   PubMedGoogle Scholar
• Forsythe RM, Xu DZ, Lu Q, et al. Lipopolysaccharide-induced enterocyte-derived nitric oxide induces intestinal monolayer permeability in an autocrine fashion. Shock. 2002;17(3):180–184.
   PubMed Web of Science ®Google Scholar
• Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108(3):761–767.
   PubMed Web of Science ®Google Scholar
• Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996;23(6):1616–1621.
   PubMed Web of Science ®Google Scholar
• Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;9:CD002907.
   PubMed Web of Science ®Google Scholar
• Kim BI, Kim HJ, Park JH, et al. Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage. J Gastroenterol Hepatol. 2011;26(3):550–557.
   PubMed Web of Science ®Google Scholar
• Guarner C, Runyon BA, Heck M, et al. Effect of long-term trimethoprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis, and survival in cirrhotic rats. Dig Dis Sci. 1999;44(10):1957–1962.
   PubMed Web of Science ®Google Scholar
• Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med. 2003;139(3):186–193.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29(9):992–999.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450–455.
   PubMed Web of Science ®Google Scholar
• Gomez-Hurtado I, Santacruz A, Peiro G, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS One. 2011;6(7):e23037.
   PubMed Web of Science ®Google Scholar
• Rogers GB, van der Gast CJ, Bruce KD, et al. Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One. 2013;8(9):e74884.
   PubMed Web of Science ®Google Scholar
• Hanouneh MA, Hanouneh IA, Hashash JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46(8):709–715.
   PubMed Web of Science ®Google Scholar
• Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992;103(4):1267–1272.
   PubMed Web of Science ®Google Scholar
• Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12(4 Pt 1):716–724.
   PubMed Web of Science ®Google Scholar
• Parekh PJ, Balart LA. Ammonia and its role in the pathogenesis of hepatic encephalopathy. Clin Liver Dis. 2015;19(3):529–537.
   PubMedGoogle Scholar
• Shawcross DL, Wright G, Olde Damink SW, et al. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22(1):125–138.
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166–173, 173 e161.
   PubMed Web of Science ®Google Scholar
• Olde Damink SW, Jalan R, Dejong CH. Interorgan ammonia trafficking in liver disease. Metab Brain Dis. 2009;24(1):169–181.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302(1):G168–G175.
   PubMed Web of Science ®Google Scholar
• Biesmans S, Meert TF, Bouwknecht JA, et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm. 2013;(2013:271359.
   PubMedGoogle Scholar
• Murta V, Farias MI, Pitossi FJ, et al. Chronic systemic IL-1beta exacerbates central neuroinflammation independently of the blood-brain barrier integrity. J Neuroimmunol. 2015;278:30–43.
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54(4):640–649.
   PubMed Web of Science ®Google Scholar
• Kang DJ, Betrapally NS, Ghosh SA, et al. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology. 2016;64(4):1232–1248.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Rama Rao KV, Norenberg MD. Neuroinflammation in hepatic encephalopathy: mechanistic aspects. J Clin Exp Hepatol. 2015;5(Suppl 1):S21–28.
   PubMedGoogle Scholar
• Montoliu C, Piedrafita B, Serra MA, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol. 2009;43(3):272–279.
   PubMed Web of Science ®Google Scholar
• Luo M, Li L, Yang EN, et al. Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis. Clin Res Hepatol Gastroenterol. 2013;37(4):384–390.
   PubMed Web of Science ®Google Scholar
• Jain L, Sharma BC, Sharma P, et al. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. Dig Liver Dis. 2012;44(12):1027–1031.
   PubMedGoogle Scholar
• Goral V, Atayan Y, Kaplan A. The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor alpha? Hepatogastroenterology. 2011;58(107–108):943–948.
   PubMedGoogle Scholar
• Wright G, Davies NA, Shawcross DL, et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology. 2007;45(6):1517–1526.
   PubMed Web of Science ®Google Scholar
• Sanderson DJ, Good MA, Seeburg PH, et al. The role of the GluR-A (GluR1) AMPA receptor subunit in learning and memory. Prog Brain Res. 2008;169:159–178.
   PubMed Web of Science ®Google Scholar
• Wiltgen BJ, Royle GA, Gray EE, et al. A role for calcium-permeable AMPA receptors in synaptic plasticity and learning. PLoS One. 2010;5:9.
   PubMed Web of Science ®Google Scholar
• Lai AY, Swayze RD, El-Husseini A, et al. Interleukin-1 beta modulates AMPA receptor expression and phosphorylation in hippocampal neurons. J Neuroimmunol. 2006;175(1–2):97–106.
   PubMed Web of Science ®Google Scholar
• Ogoshi F, Yin HZ, Kuppumbatti Y, et al. Tumor necrosis-factor-alpha (TNF-alpha) induces rapid insertion of Ca2+-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/kainate (Ca-A/K) channels in a subset of hippocampal pyramidal neurons. Exp Neurol. 2005;193(2):384–393.
   PubMed Web of Science ®Google Scholar
• Dadsetan S, Balzano T, Forteza J, et al. Reducing peripheral inflammation with infliximab reduces neuroinflammation and improves cognition in rats with hepatic encephalopathy. Front Mol Neurosci. 2016;9:106.
   PubMed Web of Science ®Google Scholar
• Cheng X, Shen Y, Targeting LR. TNF: a therapeutic strategy for Alzheimer’s disease. Drug Discov Today. 2014;19(11):1822–1827.
   PubMed Web of Science ®Google Scholar
• Cagnin A, Taylor-Robinson SD, Forton DM, et al. In vivo imaging of cerebral “peripheral benzodiazepine binding sites” in patients with hepatic encephalopathy. Gut. 2006;55(4):547–553.
   PubMed Web of Science ®Google Scholar
• Felipo V, Urios A, Montesinos E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis. 2012;27(1):51–58.
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40(2):247–254.
   PubMed Web of Science ®Google Scholar
• Rodrigo R, Cauli O, Gomez-Pinedo U, et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology. 2010;139(2):675–684.
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited. Metab Brain Dis. 2016;31(6):1211–1215.
   PubMed Web of Science ®Google Scholar
• Moratalla A, Ampuero J, Bellot P, et al. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int. 2017;37(2):212–223.
   PubMed Web of Science ®Google Scholar
• O’Hair DP, Adams MB, Tunberg TC, et al. Relationships among endotoxemia, arterial pressure, and renal function in dogs. Circ Shock. 1989;27(3):199–210.
   PubMedGoogle Scholar
• Huang LT, Hung JF, Chen CC, et al. Endotoxemia exacerbates kidney injury and increases asymmetric dimethylarginine in young bile duct-ligated rats. Shock. 2012;37(4):441–448.
   PubMed Web of Science ®Google Scholar
• Uchihara M, Izumi N, Sato C, et al. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology. 1992;16(1):95–99.
   PubMed Web of Science ®Google Scholar
• Shah N, Dhar D. El Zahraa Mohammed F et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol. 2012;56(5):1047–1053.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez R, Noiret L, Sen S, et al. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury. Liver Int. 2015;35(2):335–343.
   PubMed Web of Science ®Google Scholar
• Tarao K, Moroi T, Hirabayashi Y, et al. Effect of paromomycin sulfate on endotoxemia in patients with cirrhosis. J Clin Gastroenterol. 1982;4(3):263–267.
   PubMed Web of Science ®Google Scholar
• Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012;10(7):815–818.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Zocco MA, Senzolo M, et al. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. Transplant Rev (Orlando). 2014;28(2):92–101.
   PubMedGoogle Scholar
• Ponziani FR, Zocco MA, Garcovich M, et al. What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol. 2012;18(36):5014–5020.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Zocco MA, Tortora A, et al. Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients? Expert Opin Pharmacother. 2010;11(9):1479–1487.
   PubMed Web of Science ®Google Scholar
• Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–689.
   PubMed Web of Science ®Google Scholar
• Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736–741.
   PubMed Web of Science ®Google Scholar
• Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–348.
   PubMed Web of Science ®Google Scholar
• Lancellotti S, Basso M, Veca V, et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med. 2016;11(7):959–967.
   PubMed Web of Science ®Google Scholar
• Violi F, Ferro D, Basili S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost. 1997;77(1):44–47.
   PubMed Web of Science ®Google Scholar
• Wosiewicz P, Zorniak M, Hartleb M, et al. Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability. Clin Res Hepatol Gastroenterol. 2016;40(6):722–729.
   PubMed Web of Science ®Google Scholar
• Sun Z, Wang X, Andersson R. Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology. Dig Surg. 1998;15(5):386–397.
   PubMed Web of Science ®Google Scholar
• Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut. 2006;55(10):1512–1520.
   PubMed Web of Science ®Google Scholar
• Menzies V. Absorption of intact oligosaccharide in health and disease. Biochem Soc Trans. 1974;2(5):1042–1047.
   Web of Science ®Google Scholar
• van Wijck K, Verlinden TJ, van Eijk HM, et al. Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial. Clin Nutr. 2013;32(2):245–251.
   PubMed Web of Science ®Google Scholar
• Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis. 2010;42(3):200–204.
   PubMedGoogle Scholar
• Vogt A, Reuken PA, Stengel S, et al. Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study. World J Gastroenterol. 2016;22(11):3275–3284.
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Verhoef M, Wallace JL, et al. A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet. 1994;343(8904):998–1000.
   PubMed Web of Science ®Google Scholar
• Meddings JB, Gibbons I. Discrimination of site-specific alterations in gastrointestinal permeability in the rat. Gastroenterology. 1998;114(1):83–92.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Peters TJ, Veall N. A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet. 1983;1(8320):323–325.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2(8413):1171–1174.
   PubMed Web of Science ®Google Scholar
• Rossi M, Sganga G, Mazzone M, et al. Cardiopulmonary bypass in man: role of the intestine in a self-limiting inflammatory response with demonstrable bacterial translocation. Ann Thorac Surg. 2004;77(2):612–618.
   PubMed Web of Science ®Google Scholar
• Ma TY, Hollander D, Krugliak P, et al. PEG 400, a hydrophilic molecular probe for measuring intestinal permeability. Gastroenterology. 1990;98(1):39–46.
   PubMed Web of Science ®Google Scholar
• Hollander D, Koyama S, Dadufalza V, et al. Polyethylene glycol 900 permeability of rat intestinal and colonic segments in vivo and brush border membrane vesicles in vitro. J Lab Clin Med. 1989;113(4):505–515.
   PubMed Web of Science ®Google Scholar
• Falth-Magnusson K, Jansson G, Stenhammar L, et al. Intestinal permeability assessed with different-sized polyethylene glycols in children undergoing small-intestinal biopsy for suspected celiac disease. Scand J Gastroenterol. 1989;24(1):40–46.
   PubMed Web of Science ®Google Scholar
• Maxton DG, Bjarnason I, Reynolds AP, et al. Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci (Lond). 1986;71(1):71–80.
   PubMed Web of Science ®Google Scholar
• Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003;50(53):1482–1486.
   PubMed Web of Science ®Google Scholar
• Xu WH, Wu XJ, Li JS. Influence of portal pressure change on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat Dis Int. 2002;1(4):510–514.
   PubMedGoogle Scholar
• Dastych M, Dastych M Jr., Novotna H, et al. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn’s disease. Dig Dis Sci. 2008;53(10):2789–2792.
   PubMed Web of Science ®Google Scholar
• Liboredo JC, Vilela EG, Ferrari Mde L, et al. Nutrition status and intestinal permeability in patients eligible for liver transplantation. JPEN J Parenter Enteral Nutr. 2015;39(2):163–170.
   PubMed Web of Science ®Google Scholar
• Campillo B, Pernet P, Bories PN, et al. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol. 1999;11(7):755–759.
   PubMed Web of Science ®Google Scholar
• Zuckerman MJ, Menzies IS, Ho H, et al. Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. Dig Dis Sci. 2004;49(4):621–626.
   PubMed Web of Science ®Google Scholar
• Fujii T, Seki T, Maruoka M, et al. Lactulose-L-rhamnose intestinal permeability test in patients with liver cirrhosis. Hepatol Res. 2001;19(2):158–169.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–921.
   PubMed Web of Science ®Google Scholar
• Lee S, Son SC, Han MJ, et al. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World J Gastroenterol. 2008;14(24):3884–3890.
   PubMed Web of Science ®Google Scholar
• Parlesak A, Schafer C, Schutz T, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32(5):742–747.
   PubMed Web of Science ®Google Scholar
• Pijls KE, Koek GH, Elamin EE, et al. Large intestine permeability is increased in patients with compensated liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014;306(2):G147–G153.
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Valenza V, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol. 2010;105(2):323–327.
   PubMed Web of Science ®Google Scholar
• Huglo D, De Botton S, Canva-Delcambre V, et al. Simultaneous determination of pulmonary and intestinal permeability in patients with alcoholic liver cirrhosis. Eur J Nucl Med. 2001;28(10):1505–1511.
   PubMedGoogle Scholar
• Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–1887.
   PubMed Web of Science ®Google Scholar
• Giorgio V, Miele L, Principessa L, et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46(6):556–560.
   PubMedGoogle Scholar
• Di Leo V, Venturi C, Baragiotta A, et al. Gastroduodenal and intestinal permeability in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2003;15(9):967–973.
   PubMed Web of Science ®Google Scholar
• Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci (Lond). 1992;82(5):471–488.
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M, Eckert DJ, et al. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G919–G928.
   PubMed Web of Science ®Google Scholar
• Fukui H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol. 2015;7(3):425–442.
   PubMed Web of Science ®Google Scholar
• Stadlbauer V, Davies NA, Wright G, et al. Endotoxin measures in patients’ sample: how valid are the results? J Hepatol. 2007;47(5):726–727;author reply 727–723.
   PubMed Web of Science ®Google Scholar
• Prytz H, Holst-Christensen J, Korner B, et al. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Scand J Gastroenterol. 1976;11(8):857–863.
   PubMed Web of Science ®Google Scholar
• Tachiyama G, Sakon M, Kambayashi J, et al. Endogenous endotoxemia in patients with liver cirrhosis–a quantitative analysis of endotoxin in portal and peripheral blood. Jpn J Surg. 1988;18(4):403–408.
   PubMedGoogle Scholar
• Bigatello LM, Broitman SA, Fattori L, et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol. 1987;82(1):11–15.
   PubMed Web of Science ®Google Scholar
• Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol. 1987;4(1):8–14.
   PubMed Web of Science ®Google Scholar
• Fukui H, Brauner B, Bode JC, et al. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol. 1991;12(2):162–169.
   PubMed Web of Science ®Google Scholar
• Tarao K, So K, Moroi T, et al. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: its clinical significance. Gastroenterology. 1977;73(3):539–542.
   PubMed Web of Science ®Google Scholar
• Hanck C, Rossol S, Bocker U, et al. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol. 1998;33(6):606–608.
   PubMed Web of Science ®Google Scholar
• Clemente C, Bosch J, Rodes J, et al. Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis. Gut. 1977;18(7):556–560.
   PubMed Web of Science ®Google Scholar
• Chan CC, Hwang SJ, Lee FY, et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol. 1997;32(9):942–946.
   PubMed Web of Science ®Google Scholar
• Kaser A, Ludwiczek O, Waldenberger P, et al. Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting. Liver. 2002;22(5):380–387.
   PubMedGoogle Scholar
• Guerra-Ruiz A, Casafont F, Cobo M, et al. Increased bactericidal/permeability increasing protein in patients with cirrhosis. Liver Int. 2010;30(1):94–101.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141(4):1220–1230, 1230 e1221-e1223.
   PubMed Web of Science ®Google Scholar
• Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet. 2004;363(9421):1608–1610.
   PubMed Web of Science ®Google Scholar
• Agiasotelli D, Alexopoulou A, Vasilieva L, et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int. 2016;37:576-582.
   PubMed Web of Science ®Google Scholar
• Myc A, Buck J, Gonin J, et al. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol. 1997;4(2):113–116.
   PubMedGoogle Scholar
• Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008;135(1):226–233.
   PubMed Web of Science ®Google Scholar
• French AL, Evans CT, Agniel DM, et al. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis. 2013;208(4):679–689.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Imajo K, Yoneda M, et al. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One. 2013;8(6):e65211.
   PubMed Web of Science ®Google Scholar
• Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology. 2006;44(3):633–639.
   PubMed Web of Science ®Google Scholar
• Such J, Frances R, Munoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002;36(1):135–141.
   PubMed Web of Science ®Google Scholar
• Frances R, Zapater P, Gonzalez-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology. 2008;47(3):978–985.
   PubMed Web of Science ®Google Scholar
• Mostafa MS, El-Seidi EA, Kassem AM, et al. Detection of ascitic fluid infections in patients with liver cirrhosis and ascites. Arab J Gastroenterol. 2011;12(1):20–24.
   PubMedGoogle Scholar
• Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology. 2004;39(2):484–491.
   PubMed Web of Science ®Google Scholar
• El-Naggar MM. Khalil el SA, El-Daker MA, Salama MF. Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites. J Med Microbiol. 2008;57(Pt 12):1533–1538.
   PubMed Web of Science ®Google Scholar
• Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48(6):1924–1931.
   PubMed Web of Science ®Google Scholar
• Fagan KJ, Rogers GB, Melino M, et al. Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection. PLoS One. 2015;10(3):e0120642.
   PubMed Web of Science ®Google Scholar
• Rincon D, Vaquero J, Hernando A, et al. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int. 2014;34(10):1504–1512.
   PubMed Web of Science ®Google Scholar
• Mortensen C, Jensen JS, Hobolth L, et al. Association of markers of bacterial translocation with immune activation in decompensated cirrhosis. Eur J Gastroenterol Hepatol. 2014;26(12):1360–1366.
   PubMed Web of Science ®Google Scholar
• Mortensen C, Karlsen S, Gronbaek H, et al. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. Liver Int. 2013;33(9):1309–1315.
   PubMed Web of Science ®Google Scholar
• Appenrodt B, Lehmann LE, Thyssen L, et al. Is detection of bacterial DNA in ascitic fluid of clinical relevance? Eur J Gastroenterol Hepatol. 2010;22(12):1487–1494.
   PubMed Web of Science ®Google Scholar
• Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50(3):113–123.
   PubMedGoogle Scholar
• Burri E, Beglinger C, Von Felten S, et al. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60(2):485–491.
   PubMed Web of Science ®Google Scholar
• Gundling F, Schmidtler F, Hapfelmeier A, et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int. 2011;31(9):1406–1415.
   PubMed Web of Science ®Google Scholar
• Lutz P, Pfarr K, Nischalke HD, et al. The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. Clin Chem Lab Med. 2015;53(12):2031–2039.
   PubMed Web of Science ®Google Scholar
• Homann C, Garred P, Graudal N, et al. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology. 1995;21(4):979–985.
   PubMed Web of Science ®Google Scholar
• Bota DP, van Nuffelen M, Zakariah AN, et al. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med. 2005;146(6):347–351.
   PubMed Web of Science ®Google Scholar
• Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. 2003;41(2):165–170.
   PubMed Web of Science ®Google Scholar
• Cai ZH, Fan CL, Zheng JF, et al. Measurement of serum procalcitonin levels for the early diagnosis of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis. BMC Infect Dis. 2015;15:55.
   Web of Science ®Google Scholar
• Marciano S, Haddad L, Martinez AP, et al. Ultra-sensitive procalcitonin may help rule out bacterial infections in patients with cirrhosis. Ann Hepatol. 2014;13(5):541–547.
   PubMed Web of Science ®Google Scholar
• Lesinska M, Hartleb M, Gutkowski K, et al. Procalcitonin and macrophage inflammatory protein-1 beta (MIP-1beta) in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Adv Med Sci. 2014;59(1):52–56.
   PubMed Web of Science ®Google Scholar
• Cekin Y, Cekin AH, Duman A, et al. The role of serum procalcitonin levels in predicting ascitic fluid infection in hospitalized cirrhotic and non-cirrhotic patients. Int J Med Sci. 2013;10(10):1367–1374.
   PubMed Web of Science ®Google Scholar
• Su DH, Zhuo C, Liao K, et al. Value of serum procalcitonin levels in predicting spontaneous bacterial peritonitis. Hepatogastroenterology. 2013;60(124):641–646.
   PubMedGoogle Scholar
• Li CH, Yang RB, Pang JH, et al. Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department. Acad Emerg Med. 2011;18(2):121–126.
   PubMed Web of Science ®Google Scholar
• Spahr L, Morard I, Hadengue A, et al. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology. 2001;48(38):502–505.
   PubMedGoogle Scholar
• Viallon A, Zeni F, Pouzet V, et al. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med. 2000;26(8):1082–1088.
   PubMed Web of Science ®Google Scholar
• Attar BM, Moore CM, George M, et al. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. World J Gastroenterol. 2014;20(9):2374–2382.
   PubMed Web of Science ®Google Scholar
• Cervoni JP, Thevenot T, Weil D, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol. 2012;56(6):1299–1304.
   PubMed Web of Science ®Google Scholar
• Di Martino V, Coutris C, Cervoni JP, et al. Prognostic value of C-reactive protein levels in patients with cirrhosis. Liver Transpl. 2015;21(6):753–760.
   PubMed Web of Science ®Google Scholar
• Cervoni JP, Amoros A, Banares R, et al. Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort. Eur J Gastroenterol Hepatol. 2016;28(9):1028–1034.
   PubMed Web of Science ®Google Scholar
• Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–1437, 1437 e1421-e1429.
   PubMed Web of Science ®Google Scholar
• Papp M, Sipeki N, Vitalis Z, et al. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis. J Hepatol. 2013;59(3):457–466.
   PubMed Web of Science ®Google Scholar
• Ruiz-Alcaraz AJ, Martinez-Esparza M, Cano R, et al. Peritoneal macrophage priming in cirrhosis is related to ERK phosphorylation and IL-6 secretion. Eur J Clin Invest. 2011;41(1):8–15.
   PubMed Web of Science ®Google Scholar
• Kronenberger B, Rudloff I, Bachmann M, et al. Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. BMC Med. 2012;10:102.
   PubMed Web of Science ®Google Scholar
• Berry PA, Antoniades CG, Carey I, et al. Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med. 2011;37(3):453–460.
   PubMed Web of Science ®Google Scholar
• Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–777.
   PubMed Web of Science ®Google Scholar